Compare AbbVie Inc (ABBV) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Sibanye Stillwater Ltd — how do they compare? AbbVie Inc trades at $249.57 (market cap $441.94B), while Sibanye Stillwater Ltd trades at $10.72 (market cap $7.54B). The key difference: AbbVie Inc is far larger — about 58.6× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (2.93%). Which is the better fit depends on your goals.
| ABBV | SBSW | |
|---|---|---|
Market Cap | $441.94B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $21.12 |
52-Week Low | $197.38 | $7.27 |
Enterprise Value | $506.19B | $9.19B |
Dividend Yield | 2.77% | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Sibanye Stillwater (SBSW) trades at $10.67, up 0.28% with a bullish technical signal despite recent earnings misses. The stock shows attractive valuation metrics with P/E of 4.76 and P/S of 0.94, though profitability remains challenged with negative net income margin of -3.99%. Recent news highlights significant price volatility and mixed analyst views on valuation.
The outlook suggests potential upside to the $14.25 consensus price target, supported by projected cash flow improvement in 2025. Key risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Institutional sentiment leans bullish with 43% buy ratings, but investors should monitor execution on debt reduction targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
